AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04985903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A's lecture
Description: a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
Study NCT04874155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System - Active
Description: Noninvasive peripheral nerve stimulation device programmed to active mode.
Study NCT04874155 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NTX100 Neuromodulation System - Sham
Description: Noninvasive peripheral nerve stimulation device programmed to sham mode.
Study NCT04874155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTX100 Neuromodulation System - Open-Label
Description: Noninvasive peripheral nerve stimulation device programmed to active mode.
Study NCT06674954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06674954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06205355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia/Nociception Index (ANI) monitoring
Description: intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
Study NCT06205355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
Study NCT05558514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Place-based cochlear implant mapping
Description: Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
Study NCT05558514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default cochlear implant mapping
Description: At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
Study NCT05078008 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy modalities
Description: parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
Study NCT05078008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy modalities
Description: parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
Study NCT05078008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balneotherapy modalities
Description: Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
Study NCT05348603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Letter
Description: Patients receive a traditional letter.
Study NCT05348603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to Patient Message
Description: Patients receive a direct to patient message via the portal.
Study NCT05348603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Patients are contacted by a chatbot via the portal.
Study NCT05348603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banner
Description: Patients are exposed to a banner ad via the portal.
Study NCT06310031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrioVAD System
Description: Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
Study NCT06310031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate 3
Description: Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.
Study NCT06632470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome injection
Description: Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
Study NCT06632470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12 Injection
Description: Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
Study NCT06633575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
Study NCT06633432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
Study NCT06633432 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-acupuncture stimulation
Description: The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
Study NCT05460741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated exercise approach
Description: Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
Study NCT05460741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: educational program related to menstrual cycle will be given to females.
Study NCT03955224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basic Oral Care + active LLLT
Description: * Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
Study NCT03955224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic oral Care + inactive LLLT
Description: * Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)
Study NCT03955224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic Oral Care
Description: Compliance with the Basic Oral Care only
Study NCT05844098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-wire
Description: K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
Study NCT05760885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training with sensory augmentation
Description: Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
Study NCT05760885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
Study NCT06057012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-296
Description: BRII-296 will be given via intramuscular injection.
Study NCT06057012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo Medrol
Description: Depo Medrol will be given via intramuscular injection.
Study NCT04258813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iGuide Intervention (Self-guided)
Description: The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
Study NCT04258813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iGuide 2 Intervention (Tailored/Targeted)
Description: The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics.
Study NCT04258813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
Study NCT05726227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.
Study NCT05726227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously once-weekly.
Study NCT06532422 — intervention group
Intervention type: PROCEDURE
Intervention: Partial or total laparoscopic nephrectomy
Description: Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
Study NCT06570018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post operative enhanced recovery elements
Description: According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
Study NCT06324721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)
Description: Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis~Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography
Study NCT06324721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)
Description: Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)
Study NCT06324721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer
Description: Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer
Study NCT06389136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose A
Description: Oral tablet
Study NCT06389136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose A
Description: Subcutaneous (SC) injection
Study NCT06389136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose B
Description: Oral tablet
Study NCT04943289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DUOC-01
Description: DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenously (IV) Infusion
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study NCT05425394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay first bath
Description: Newborns delay first bath to 8 hours after birth
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection
Study NCT06236438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion
Study NCT06080178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-lyte (static group)
Description: Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
Study NCT06726863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport IRF
Description: Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.
Study NCT06726863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR1
Description: Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.
Study NCT06726863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR2
Description: Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
Study NCT06751290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
Study NCT06751290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
Study NCT06751290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
Study NCT06763991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage connection
Description: Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.
Study NCT06763991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage connection
Description: One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.
Study NCT06768541 — intervention group
Intervention type: PROCEDURE
Intervention: THA using a short stem
Description: Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
Study NCT06761651 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic
Study NCT05198297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Minimally invasive glaucoma surgery device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
Study NCT05198297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic surgery
Description: Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia